CCR2i  +  anti-PD-1 in cutaneous T-cell lymphoma, CCX872  +  anti-PD-1 in glioblastoma, and lefitolimod  +  anti-PD-1 in melanoma are among such examples [95]. This evidence concerns the gene PDCD1 and primary cutaneous T-cell non-Hodgkin lymphoma.